Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


Peptides Congress 2014

03 Apr 2014 - 04 Apr 2014



Bookmark and Share


Over 400 attendees working within Proteins, Antibodies, Peptides and Biotherapeutics

Over 20 case studies, presentations and panel discussions

Co-Located with our 7th Annual Proteins Congress

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present the Peptides Congress taking place on the 3rd & 4th April, 2014 at the Novotel London West, UK. Our esteemed experts will explore recent developments in peptide research from discovery and synthesis through to optimal engineering techniques and therapeutic applications.

The popularity of peptide therapeutics has increased significantly in recent years; the number of new peptides entering the clinic has doubled, and peptide therapies in the US have achieved sales over $1 billion. The Peptides Congress will bring together key decision makers and researchers in this revitalised field. On Day One, the Congress will examine various peptide discovery and synthesis techniques, whilst looking in detail at the design and production of peptide libraries and arrays, as well as synthesised and modified peptides. Our internationally renowned speakers will also give a detailed insight into protein-protein interactions and the production of bioactive peptides.

Due to their compelling potential, many major pharmaceuticals are seeing a resurgence of peptide use in their pipelines. The therapeutic potential of peptides is being embraced by the industry, and offers many novel opportunities for drug discovery. Day Two of the Congress will see discussions focus on peptide engineering, including peptidomimetics and peptide conjugation, as well as cell-penetrating peptides for molecular imaging. Additionally, our experts will discuss the potential of antimicrobial peptides in immunotherapy and as protease inhibitors in drug discovery.


The Peptides Congress is part of the highly successful Oxford Global Proteins Series.

Further information
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!